The impact of risk stratification by early bone‐marrow response in childhood lymphoblastic leukaemia: results from the United Kingdom Medical Research Council trial ALL97 and ALL97/99

No abstract is available for this paper.

• Publication year

  2009

• Venue

  British Journal of Haematology

• Publication date

  2009-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2141.2009.07769.xPMID 19549269
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.

  2008cited by this paper
• Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952.

  2007cited by this paper
• Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial.

  2006cited by this paper
• Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial

  2005cited by this paper
• Thioguanine Compared with Mercaptopurine in Childhood Lymphoblastic Leukaemia: Results of the United Kingdom Medical Research Council Randomised Trial ALL97.

  2005cited by this paper
• Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.

  2003cited by this paper
• Treatment of high risk leukaemia - Results of MRC childhood acute lymphoblastic leukaemia study MRC HR-1.

  2002cited by this paper
• Failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: lessons from the UK Medical Research Council trials UKALL X and UKALL XI

  2002cited by this paper
• Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol

  2001cited by this paper
• Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group.

  2000cited by this paper
• Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995

  2000cited by this paper
• Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Medical Research Council Childhood Leukaemia Working Party.

  2000cited by this paper
• Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995

  2000influential reference
• Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980–1997

  2000cited by this paper
• Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report

  2000cited by this paper
• Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster.

  2000cited by this paper
• Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991).

  1999cited by this paper
• Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.

  1998cited by this paper
• Improved survival with early intensification: combined results from the Medical Research Council childhood ALL randomised trials, UKALL X and UKALL XI

  1998cited by this paper
• Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia.

  1995cited by this paper
• Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials *

  1995influential reference
• Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (Report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood)

  1991cited by this paper
• The staging of childhood acute lymphoblastic leukemia: strategies of the Childrens Cancer Study Group and a three-dimensional technic of multivariate analysis.

  1986cited by this paper
• Improvement in treatment for children with acute lymphoblastic leukaemia

  1986cited by this paper
• Analysis of prognostic factors in acute lymphoblastic leukemia.

  1986cited by this paper
• Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: biologic bases for staging, stratification, and treatment.

  1986cited by this paper
• Medical Research Council leukaemia trial, UKALL VII. A report to the Council by the Working Party on Leukaemia in Childhood.

  1985cited by this paper

• 100 years of childhood acute lymphoblastic leukaemia in the UK

  2026cites this paper
• Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009.

  2025cites this paper
• High-Dose Methotrexate in Children and Young Adults With ALL and Lymphoblastic Lymphoma: Results of the Randomized Phase III Study UKALL 2011

  2025cites this paper
• Treatment outcomes in childhood acute lymphoblastic leukemia: 40-year experience from a single tertiary center in Thailand

  2023cites this paper
• Roles of apoptotic chondrocyte‐derived CXCL12 in the enhanced chondroclast recruitment following methotrexate and/or dexamethasone treatment

  2021influential citation
• Defining low-risk high hyperdiploidy in patients with paediatric acute lymphoblastic leukaemia: a retrospective analysis of data from the UKALL97/99 and UKALL2003 clinical trials

  2021cites this paper
• Early post‐induction augmented therapy improves outcome in children and adolescents with T‐cell acute lymphoblastic leukemia

  2021cites this paper
• SARS CoV-2 Antibody Persistence During Induction Chemotherapy for Pediatric T-Cell Acute Lymphoblastic Leukemia.

  2021cites this paper
• Excess morbidity and mortality among survivors of childhood acute lymphoblastic leukaemia: 25 years of follow-up from the United Kingdom Childhood Cancer Study (UKCCS) population-based matched cohort

  2021cites this paper
• Optimizing Therapy in the Modern Age: Differences in Length of Maintenance Therapy in Acute Lymphoblastic Leukemia.

  2020cites this paper
• Prevalence, distribution and predictive value of XPO1 mutation in a real‐life chronic lymphocytic leukaemia cohort

  2020cites this paper
• A comparison of late mortality among survivors of childhood cancer in the United States and United Kingdom.

  2020cites this paper
• Challenges of starting treatment protocols for acute lymphoblastic leukaemia in a low‐income setting — the Blantyre experience

  2020cites this paper
• HAP1 loss confers l-asparaginase resistance in ALL by downregulating the calpain-1-Bid-caspase-3/12 pathway.

  2019cites this paper
• Long‐term survival after childhood acute lymphoblastic leukaemia: population‐based trends in cure and relapse by clinical characteristics

  2018cites this paper
• Synergistic action of dual IGF1/R and MEK inhibition sensitizes childhood acute lymphoblastic leukemia (ALL) cells to cytotoxic agents and involves downregulation of STAT6 and PDAP1

  2018cites this paper
• Synergistic action of dual IGF 1 / R and MEK inhibition sensitizes childhood acute lymphoblastic leukemia ( ALL ) cells to cytotoxic agents and involves downregulation of STAT 6 and PDAP 1 TaggedPD 1 X XD 2 X X

  2018cites this paper
• Relapsed Acute Lymphoblastic Leukemia of Childhood

  2017cites this paper
• Identifying Cardiovascular Risk in Survivors of Childhood Leukaemia Treated with Haematopoietic Stem Cell Transplantation and Total Body Irradiation


  2017cites this paper
• Machine learning applications for prediction of relapse in childhood acute lymphoblastic leukemia

  2017cites this paper
• CD38+ CD58- is an independent adverse prognostic factor in paediatric Philadelphia chromosome negative B cell acute lymphoblastic leukaemia patients.

  2016cites this paper
• Treatment of children with acute lymphoblastic leukemia with risk group based intensification and omission of cranial irradiation: A Korean study of 295 patients

  2016cites this paper
• Excellent outcome of minimal residual disease-defined low-risk patients is sustained with more than 10 years follow-up: results of UK paediatric acute lymphoblastic leukaemia trials 1997–2003

  2016cites this paper
• Survival of childhood acute lymphoid leukaemia in Yorkshire by clinical trial era, 1990–2011

  2015cites this paper
• Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia

  2015cites this paper
• How can we improve on the already impressive results in pediatric ALL?

  2015cites this paper
• Using nonrandomized studies to inform complex clinical decisions: The thorny issue of cranial radiation therapy for T‐cell acute lymphoblastic leukemia

  2015cites this paper
• Reduced insulin sensitivity in childhood survivors of haematopoietic stem cell transplantation is associated with lipodystropic and sarcopenic phenotypes

  2015cites this paper
• Reduced beta‐cell reserve and pancreatic volume in survivors of childhood acute lymphoblastic leukaemia treated with bone marrow transplantation and total body irradiation

  2015cites this paper
• Cranial radiation for pediatric T‐lineage acute lymphoblastic leukemia: A systematic review and meta‐analysis

  2014cites this paper
• Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.

  2014cites this paper
• Minimal Residual Disease–based Treatment is Adequate for Relapse-prone Childhood Acute Lymphoblastic Leukemia with an intrachromosomal amplification of chromosome 21: The experience of the ALL-BFM 2000 trial

  2014cites this paper
• Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics

  2014cites this paper
• Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.

  2013cites this paper
• Long-term follow-up of ETV6–RUNX1 ALL reveals that NCI risk, rather than secondary genetic abnormalities, is the key risk factor

  2013cites this paper
• Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials.

  2013cites this paper
• Diagnosis and Treatment of Childhood Acute Lymphoblastic Leukemia

  2013cites this paper
• BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia

  2013cites this paper
• Pediatric Relapsed or Refractory Leukemia: New Pharmacotherapeutic Developments and Future Directions

  2013cites this paper
• Comparing doctors' and nurses' accounts of how they provide emotional care for parents of children with acute lymphoblastic leukaemia

  2013cites this paper
• Population survival from childhood cancer in Britain during 1978-2005 by eras of entry to clinical trials.

  2012influential citation
• Childhood Leukemias: History of leukemia: historical perspectives

  2012cites this paper
• Evidence for under-diagnosis of childhood acute lymphoblastic leukaemia in poorer communities within Great Britain

  2012cites this paper
• HLA-DPβ1 Asp84-Lys69 antigen-binding signature predicts event-free survival in childhood B-cell precursor acute lymphoblastic leukaemia: results from the MRC UKALL XI childhood ALL trial

  2012cites this paper
• A remembrance: James B. Nachman 1948-2011.

  2011cites this paper
• Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis

  2011cites this paper
• The frequency and prognostic impact of dic(9;20)(p13.2;q11.2) in childhood B-cell precursor acute lymphoblastic leukemia: results from the NOPHO ALL-2000 trial

  2011cites this paper
• Outcome of childhood acute lymphoblastic leukemia in Jordan

  2011cites this paper
• Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial.

  2011cites this paper
• Pathobiology and prevention of cancer chemotherapy-induced bone growth arrest, bone loss, and osteonecrosis.

  2011cites this paper
• Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia

  2011cites this paper
• James B. Nachman, 1948 to 2011: a remembrance.

  2011cites this paper
• Balancing high accrual and ethical recruitment in paediatric oncology: a qualitative study of the 'look and feel' of clinical trial discussions

  2010cites this paper
• Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial.

  2010cites this paper
• Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute Lymphoblastic leukaemia, 1980–2001

  2009cites this paper
• Temporal changes in incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council Trials, 1985–2001

  2009cites this paper